Q & A Webcasts

Please click on a question to view webcast:

 
Speaker: Robert S. Brown, Jr., MD, MPH
1 Should I order HCV resistance testing before I start DAA therapy for all patients? If not all, which patients?
2 If my patient failed DAA therapy, how long must I wait before I can retreat that patient with a different DAA regimen?
3 If my patient doesn’t achieve SVR, do I need to order HCV resistance testing at the time of failure?
4 If my GT1a infected patient previously failed an NS5A containing regimen and has resistance variants detected, what are my options for retreatment?
5 What options do I have for my GT3 infected patient with compensated cirrhosis who previously failed SOF + NS5A inhibitor and has NS5A RAVs?
 
 
Speaker: Douglas Dieterich, MD
1 How often should I order HCV RNA for a patient prescribed a 12-week regimen? What about a 24-week regimen?
2 If my patient has severe renal impairment, are there any DAA regimens that shouldn’t be used or require extra caution?
3 If my GT1 infected patient has severe hepatic impairment and is listed, should I treat him now or wait until after transplant?
4 Can I solely rely on a serum test to define the stage of fibrosis for all patients or must I order transient elastography or a liver biopsy?
5 Is there a certain subgroup of HCV infected individuals that require liver biopsy prior to treatment?
 
 
Speaker: Ira Jacobson, MD
1 Do I need to screen all of my HCV treated patients for hepatocellular carcinoma or just those who don’t achieve sustained virologic response?
2 Is there a higher risk for HCC in HCV infected patients treated with direct acting antivirals compared to those who were treated with pegylated interferon?
3 Do I really need to screen all of my patients for hepatitis B before starting HCV therapy? Why?
4 If my patients is on a proton pump inhibitor prior to HCV DAA therapy, do I need to modify the PPI dosing with any of the DAA regimens?
5 What is the best way to manage my GT1a infected patient who is seeking treatment and currently taking amiodarone?
 
 

Target Audience - The educational initiative is intended for physicians, allied professionals, residents, fellows, and students from the specialties that we anticipate will be screening for, referring, and treating HCV and liver disease.

Statement of Need - The purpose of the activity to provide strategies to prevent disease, educate health care providers about the disease, increase disease surveillance, and improve the therapeutic management and patient outcomes.

Disclosure of Conflicts of Interest
Dr. Robert Brown is a Consultant/Advisor for AbbVie, Gilead, Merck, Janssen and Salix.

Dr. Douglas Dieterich is a Consultant/Advisor for AbbVie, Bristol-Myers Squibb and Gilead. He has received compensation for consulting fees from AbbVie and Merck.

Dr. Ira Jacobson is a Consultant/Advisor for AbbVie, Achillion, Bristol- Myers Squibb, Intercept, Gilead, Janssen, Merck, and Trek. He has received Grants/Research Support from AbbVie, Bristol-Myers Squibb, Gilead, Janssen, and Merck. Dr. Jacobson has participated in a Speaker's Bureau for AbbVie, Bristol-Myers Squibb, Gilead, and Janssen.

Medium There are no fees for participating in or receiving credit for this online activity.

Hardware/software requirements Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox, and Google Chrome.

Privacy and Confidentiality Policy The Icahn School of Medicine protects the privacy of personal and other information regarding participants and educational collaborations. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

Disclaimer – The information provided in this webcast is for continuing education purposes only. The content is not meant to provide medical judgment, diagnostic or treatment options for any medical condition. Use of this information is not suitable outside the scope of this activity.

Contact Information: For technical assistance, contact info@focusmeded.com.

Copyright - This material is protected by copyright and other intellectual property laws. It may not be otherwise copied, printed, transmitted, or published unless explicit permission is obtained. To request permission, please contact us at info@focusmeded.com.

Commercial Support - This activity is supported from independent educational grants from AbbVie, Bristol-Myers Squibb, Gilead and Merck.